Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Saved in:
Bibliographic Details
Title: Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.
Authors: Dendorfer SM; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.; Cognium GmbH, Bern, Switzerland., Schmidt-Brücken K; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Kramer M; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Steffen B; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany., Schliemann C; Department of Medicine A, University Hospital Münster, Münster, Germany., Mikesch JH; Department of Medicine A, University Hospital Münster, Münster, Germany., Alakel N; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Herbst R; Department of Internal Medicine III, Chemnitz Hospital, Chemnitz, Germany., Hänel M; Department of Internal Medicine III, Chemnitz Hospital, Chemnitz, Germany., Hanoun M; Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Kaufmann M; Department of Hematology, Robert-Bosch-Krankenhaus, Stuttgart, Germany., Weinbergerova B; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Schäfer-Eckart K; Department of Internal Medicine V, Nuremberg Hospital North, Paracelsus Medical University, Nuremberg, Germany., Sauer T; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Neubauer A; Department of Internal Medicine, Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany., Burchert A; Department of Internal Medicine, Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany., Baldus CD; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Mertová J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic., Jost E; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital Aachen & CIO ABCD Aachen, RWTH Aachen, Aachen, Germany., Niemann D; Department of Hematology, Oncology and Palliative Care, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany., Novák J; Department of Haematology, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic., Krause SW; Department of Internal Medicine V, University Hospital Erlangen, Erlangen, Germany., Scholl S; Department of Internal Medicine, University Hospital Jena, Jena, Germany., Hochhaus A; Department of Internal Medicine, University Hospital Jena, Jena, Germany., Held G; Department of Internal Medicine I, Westpfalzklinikum, Kaiserslautern, Germany., Szotkowski T; Department of Hemato-Oncology, Palacký University, Olomouc, Czech Republic., Rank A; II. Medical Clinic, University Hospital Augsburg, Augsburg, Germany., Schmid C; II. Medical Clinic, University Hospital Augsburg, Augsburg, Germany., Fransecky L; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Kayser S; Department of Internal Medicine I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Schaich M; Department of Hematology, Oncology and Palliative Care, Rems-Murr-Klinikum, Winnenden, Germany., Fiebig F; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Haake A; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Schetelig J; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Middeke JM; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Stölzel F; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Platzbecker U; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Thiede C; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.; Agendix GmbH, Dresden, Germany., Müller-Tidow C; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Berdel WE; Department of Medicine A, University Hospital Münster, Münster, Germany., Ehninger G; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Mayer J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Serve H; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany., Bornhäuser M; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Röllig C; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Source: American journal of hematology [Am J Hematol] 2026 Mar; Vol. 101 (3), pp. 512-520. Date of Electronic Publication: 2026 Jan 05.
Publication Type: Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1096-8652
DOI:10.1002/ajh.70160